Inserm Transfert
Overview
Inserm Transfert is a life sciences investment firm and technology transfer subsidiary of the French National Institute of Health and Medical Research (Inserm) that manages the valorization and transfer of research innovations to the industrial sector.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Vayyar | Nov 2019 | Series D | Co-investor |
| Hemarina | Jul 2012 | Series B | Co-investor |
| AndzonBio1 | Oct 2024 | Seed | Co-investor |
| ENYO Pharma | Jun 2018 | Series B | - |
| Inotrem | Mar 2014 | Series A | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Inserm Transfert based?
Inserm Transfert is headquartered in Paris, France.
When was Inserm Transfert founded?
Inserm Transfert was founded in 2000.
How many portfolio companies does Inserm Transfert have?
Inserm Transfert has 12 portfolio companies in Caplight's dataset.
What are some companies in Inserm Transfert's portfolio?
Portfolio companies visible on Caplight include Vayyar, Hemarina, AndzonBio1, ENYO Pharma, Inotrem.
What was Inserm Transfert's most recent investment shown here?
Inserm Transfert's most recent investment in this portfolio sample was in AndzonBio1 in 2024.
What sectors does Inserm Transfert focus on?
Inserm Transfert focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Mobility, Transportation & Logistics, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Inserm Transfert focus on?
Inserm Transfert typically invests at the MultiStage stage.
What is Inserm Transfert's AUM?
Inserm Transfert's assets under management are estimated between $50.0M and $100.0M.